A biochip built for the next pandemic can test dozens of viral antigens at once

In 2020, as scientists around the world were racing to understand COVID-19, Prof. Roy Bar-Ziv and his team at the Weizmann ...

Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data

Kymera Therapeutics (KYMR) just checked two big boxes for biotech investors, pairing strong Phase 1b data for its oral STAT6 degrader KT-621 with an FDA Fast Track nod in atopic dermatitis. See our ...

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...
Watertown Public Opinion

South Dakota revs up for the future in Biotech

After nearly 30 years of planning, the University of South Dakota Discovery District now provides lab and office space to ...